Inactive Instrument

Immutep Ltd Australian S.E.

Equities

AU000000PRR9

Biotechnology & Medical Research

Prima BioMed Limited : 29 January 2013 Prima Biomed to present at the 15th Annual BIO CEO & Investor Conference >>

January 29, 2013 at 07:09 am EST

MarketScreener.com By

SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ("Prima", "the Company") has announced today that Matthew Lehman, its Chief Executive Officer, will present at the 15th Annual BIO CEO & Investor Conference on Tuesday, 12 February 2013 at 11:30am Eastern US Time in New York, NY. Mr. Lehman will provide an overview of the Company and its corporate activities.

The presentation will be a live audio webcast and may be accessed by visiting Prima BioMed's website. A replay of the webcast will be available for 90 days following the presentation.

distributed by

Latest news about Immutep Ltd

Sector Update: Health Care Stocks Higher in Late Afternoon Trading	Jul. 12	MT
Sector Update: Health Care Stocks Rise in Afternoon Trading	Jul. 12	MT
Top Midday Gainers	Jul. 12	MT
Sector Update: Health Care Stocks Mixed Premarket Friday	Jul. 12	MT
Sector Update: Health Care	Jul. 12	MT
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Friday as Big Bank Earnings Kick Off Earnings Season	Jul. 12	MT
Top Premarket Gainers	Jul. 12	MT
Immutep Achieves 'Positive' Results From Cohort B of Phase 2B Cancer Trial; Shares Rise Pre-Bell	Jul. 12	MT
Rising US Rate Cut Bets Lift Australian Shares to Record High	Jul. 12	MT
Immutep Surges 19% Following Positive Results in Head, Neck Cancer Trial	Jul. 12	MT
Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative Pd-L1 Expression	Jul. 11	CI
Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer	Jun. 28	CI
ADRs End Flat; Alarum Technologies Climbs 26%	Jun. 27	DJ
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data	Jun. 27	MT
Baird Trims Immutep Price Target to $6 From $7, Maintains Outperform Rating	Jun. 27	MT
Immutep Reports Positive Results in Drug Combination Trial for Head, Neck Cancer	Jun. 27	MT
Immutep Gets Exclusive Rights to Develop, Commercialize New Anti-LAG-3 Small Molecules	Jun. 25	MT
Immutep Signs Agreement with Cardiff University for Development Cancer Treatment	Jun. 24	MT
Immutep Completes Nearly AU$11 Million Retail Entitlement Offer	Jun. 24	MT
Immutep Completes Stock Offering	Jun. 05	MT
Immutep, Merck Collaborate on Trial for Lung Cancer Therapy	Jun. 03	MT
Immutep, Merck Partner for Efti and Keytruda Combo in Lung Cancer Trial	Jun. 03	MT
Immutep Raising AU$100 Million for Phase Three Trial	Jun. 02	MT
Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial	Jun. 02	CI
Capital One Initiates Immutep at Overweight Rating With $10 Price Target	May. 17	MT

Chart Immutep Ltd

Duration

Period

More charts

Company Profile

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3âs ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.

Sector

Biotechnology & Medical Research

Calendar

2024-08-12 - CG Growth Conference

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+22.10%	46.55B
LONZA GROUP AG	+46.45%	41.84B
IQVIA HOLDINGS INC.	-3.12%	40.84B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B
CELLTRION, INC.	-6.30%	28.27B
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B
MEDPACE HOLDINGS, INC.	+44.52%	13.69B
BIO-TECHNE CORPORATION	+0.19%	12.18B

Other Biotechnology & Medical Research